SCHEMBL4014784

SCHEMBL4014784

Cc1ccc(-c2[c]c3ccccc3n2C)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.35
KDM4E B2RXH2 5/20 0.35
HSD17B10 Q99714 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAPT P10636 3/20 0.34
LMNA P02545 2/20 0.34
HTT P42858 1/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
GPR3 P46089 1/20 0.33
HPGD P15428 2/20 0.33
NPC1 O15118 6/20 0.33
RAB9A P51151 6/20 0.33
KMT2A Q03164 3/20 0.33
GAA P10253 2/20 0.33
PKM P14618 2/20 0.33
TP53 P04637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700437 0.72 GPR3 (0.41) ALDH1A1KDM4EHSD17B10CYP2C19MAPT
SCHEMBL5545557 0.69 AGTR1 (0.53) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7035643 0.67 GPR3 (0.39) ALDH1A1KDM4ETSHRMAPTGPR3
SCHEMBL7036048 0.67 SMN1; SMN2 (0.41) ALDH1A1MAPTLMNAHTTBCHE
SCHEMBL4014977 0.66 L3MBTL1 (0.38) ALDH1A1KDM4EHSD17B10CYP1A2TSHR
Tannin Pyrogallol SCHEMBL1419994 0.59 ACHE (0.62) ALDH1A1KDM4EHSD17B10CYP1A2CYP3A4
SCHEMBL587 0.59 ACHE (0.62) ALDH1A1KDM4EHSD17B10CYP1A2CYP3A4
SCHEMBL7412470 0.59 ACHE (0.62) ALDH1A1KDM4EHSD17B10CYP1A2CYP3A4
SCHEMBL22079642 0.59 ACHE (0.62) ALDH1A1KDM4EHSD17B10CYP1A2CYP3A4
SCHEMBL14867549 0.58 TDP1 (0.44) ALDH1A1KDM4EHSD17B10TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US claimed
JP-2006501194-A 2006-01-12 JP claimed
EP-1525190-A1 CCK-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2005-04-27 EP claimed
WO-2004007463-A1 CCK-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2004-01-22 WO claimed
EP-1781617-A4 ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARMACEUTICA NV (BE) 2009-06-24 EP disclosed
US-7465808-B2 CCK-1 receptor modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2008-12-16 US disclosed
EP-1781617-A2 ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-09 EP disclosed
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
EP-1641762-A2 CCK-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-04-05 EP disclosed
US-20060014817-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2006-01-19 US disclosed
WO-2006004742-A2 α, β-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARAMCEUTICA N.V. (BE) 2006-01-12 WO disclosed
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-05 US disclosed
EP-1525190-A1 CCK-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2005-04-27 EP disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed
WO-2005005393-A2 CCK-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2005-01-20 WO disclosed
WO-2004007463-A1 CCK-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R ALDH1A1 1572/4885KDM4E 3706/4885HSD17B10 1195/4885
US-20060014817-A1 CCK-1 receptor modulators CCKAR, CCKBR, GIPR ALDH1A1 2402/4885KDM4E 3601/4885HSD17B10 2662/4885
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration CCKAR, CCKBR, FFAR1 ALDH1A1 597/4885KDM4E 4599/4885HSD17B10 320/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R ALDH1A1 1501/4885KDM4E 3040/4885HSD17B10 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.